Activity
(Figure-1: Antiproliferative activity of Samceptin was assayed in comparison with Herceptin using ADCC Reporter Bioassay Kit in SK-BR-3 cells. Result indicated that Samceptin potency is at par with Herceptin.)
ErbB2/HER2 recombinant antibody
Recombinant anti-human ErbB2/HER2 Antibody (Trastuzumab) FITC Conjugated
ADCC: 20-25mg/ml
Shipping: Blue Ice pack
Activity
(Figure-1: Antiproliferative activity of Samceptin was assayed in comparison with Herceptin using ADCC Reporter Bioassay Kit in SK-BR-3 cells. Result indicated that Samceptin potency is at par with Herceptin.)
Activity
(Figure-1: Antiproliferative activity of Samceptin was assayed in comparison with Herceptin using ADCC Reporter Bioassay Kit in SK-BR-3 cells. Result indicated that Samceptin potency is at par with Herceptin.)
Activity
(Figure-2: Antiproliferative activity of Samceptin was assayed in comparison with Herceptin using ADCC Reporter Bioassay Kit from Promega in MCF-7 cells. Result indicated that Samceptin potency is at par with Herceptin.)
Activity
(Figure-2: Antiproliferative activity of Samceptin was assayed in comparison with Herceptin using ADCC Reporter Bioassay Kit from Promega in MCF-7 cells. Result indicated that Samceptin potency is at par with Herceptin.)
Activity
(Figure-3: SEC-HPLC analysis of Herceptin and Samceptin. Based on this analysis, Samceptin is highly pure and purity estimated to be >98%)
Activity
(Figure-3: SEC-HPLC analysis of Herceptin and Samceptin. Based on this analysis, Samceptin is highly pure and purity estimated to be >98%)
SDS-Page
(Figure-4: Reducing SDS-PGE of Samceptin (Lane-1) in comparison with Herceptin (Lane-2). Lanes were overloaded to show the presence of any other protein bands than Samceptin. Both heavy and light chains are well separated.)
SDS-Page
(Figure-4: Reducing SDS-PGE of Samceptin (Lane-1) in comparison with Herceptin (Lane-2). Lanes were overloaded to show the presence of any other protein bands than Samceptin. Both heavy and light chains are well separated.)
Flow Cytometry (FC/FACS)
(Figure-5: Epitope binding study by flow cytometric analysis. BT-474 cells expressing HER2 antigen were treated with Herceptin and Samceptin (2 ug/10^6 Cells). Surface staining was done using FITC conjugated antibodies.)
Flow Cytometry (FC/FACS)
(Figure-5: Epitope binding study by flow cytometric analysis. BT-474 cells expressing HER2 antigen were treated with Herceptin and Samceptin (2 ug/10^6 Cells). Surface staining was done using FITC conjugated antibodies.)
Flow Cytometry (FC/FACS)
(Figure-6: Epitope binding study by flow cytometric analysis. MCF-7 cells expressing HER2 antigen were treated with Herceptin and Samceptin (2 ug/10^6 Cells). Surface staining was done using FITC conjugated antibodies.)
Flow Cytometry (FC/FACS)
(Figure-6: Epitope binding study by flow cytometric analysis. MCF-7 cells expressing HER2 antigen were treated with Herceptin and Samceptin (2 ug/10^6 Cells). Surface staining was done using FITC conjugated antibodies.)
NCBI and Uniprot Product Information
NCBI Description
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]
Uniprot Description
HER2: a proto-oncogenic receptor tyrosine kinase of the EGFR family. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. Not activated by EGF, TGF- alpha and amphiregulin. Amplified in breast cancer. Overexpression induces constitutive activity, and the gene is amplified or overexpressed in up to 30% of breast cancers, correlating with poor survival. The antibody Herceptin is approved for treatment of metastatic breast cancer with HER2 amplification/overexpression. Somatic mutations seen in 4% of lung cancers and also in breast, gastric, ovarian cancer and glioblastoma. One SNP shows predisposition to breast and gastric cancer. Inhibitors: Herceptin, lapatinib, PKI-166, EKB-569, CI-1033.
Protein type: Protein kinase, tyrosine (receptor); Kinase, protein; EC 2.7.10.1; Protein kinase, TK; Membrane protein, integral; Oncoprotein; TK group; EGFR family
Chromosomal Location of Human Ortholog: 17q12
Cellular Component: perinuclear region of cytoplasm; basolateral plasma membrane; cytoplasm; apical plasma membrane; integral to membrane; plasma membrane; endosome membrane; cytoplasmic vesicle; nucleus; receptor complex
Molecular Function: protein dimerization activity; protein C-terminus binding; identical protein binding; protein binding; transmembrane receptor activity; ErbB-3 class receptor binding; protein heterodimerization activity; protein-tyrosine kinase activity; growth factor binding; transmembrane receptor protein tyrosine kinase activity; receptor signaling protein tyrosine kinase activity; protein phosphatase binding; ATP binding
Biological Process: myelination; axon guidance; phosphoinositide 3-kinase cascade; peptidyl-tyrosine phosphorylation; positive regulation of cell adhesion; wound healing; nerve growth factor receptor signaling pathway; positive regulation of translation; heart development; protein amino acid autophosphorylation; motor axon guidance; signal transduction; enzyme linked receptor protein signaling pathway; protein amino acid phosphorylation; positive regulation of transcription from RNA polymerase I promoter; positive regulation of MAP kinase activity; cell surface receptor linked signal transduction; oligodendrocyte differentiation; neuromuscular junction development; epidermal growth factor receptor signaling pathway; negative regulation of immature T cell proliferation in the thymus; regulation of microtubule-based process; phosphoinositide-mediated signaling; fibroblast growth factor receptor signaling pathway; transcription, DNA-dependent; regulation of angiogenesis; positive regulation of cell growth; peripheral nervous system development; cell proliferation; positive regulation of transcription from RNA polymerase III promoter; innate immune response; positive regulation of protein amino acid phosphorylation; positive regulation of epithelial cell proliferation; transmembrane receptor protein tyrosine kinase signaling pathway
Disease: Gastric Cancer; Lung Cancer; Glioma Susceptibility 1
Research Articles on ErbB2/HER2
Similar Products
Product Notes
The ErbB2/HER2 erbb2 (Catalog #AAA669500) is a Recombinant Antibody produced from CHO cells and is intended for research purposes only. The product is available for immediate purchase. The Recombinant anti-human ErbB2/HER2 Antibody (Trastuzumab) FITC Conjugated reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's ErbB2/HER2 can be used in a range of immunoassay formats including, but not limited to, Functional Assay (FA), Flow Cytometry (FC/FACS), Antibody-Dependent Cellular Cytotoxicity (ADCC). FC/FACS: 1-2ug/10^6 cells ADCC: 20-25mg/ml. Researchers should empirically determine the suitability of the ErbB2/HER2 erbb2 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "ErbB2/HER2, Monoclonal Recombinant Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
